Pfiz­er ax­es sick­le cell, be­ta tha­lassemia deal with Sy­ros

Pfiz­er ter­mi­nat­ed a deal that Sy­ros Phar­ma­ceu­ti­cals made with Glob­al Blood Ther­a­peu­tics to de­vel­op treat­ments for be­ta tha­lassemia and sick­le cell dis­ease.

Pfiz­er

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER